November 25, 2020

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity

• A repeated cross-sectional study carried out in all 50 US states, the District of Columbia, and Puerto Rico found that although SARS-CoV-2 seroprevalence varied between 1% and 23%, fewer than 10% of people nationally had detectable antibodies. A total of 177,919 samples were obtained during four periods between July 27 and September 24, 2020 from people presenting to a healthcare setting for routine screening or clinical care. As of the final collection of samples, the seroprevalence in Washington State was estimated to be under 5%.

Bajema et al. (Nov 2020). Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.7976